Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Chief Operating Officer | February 13, 2023 | February 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date February 13, 2023 · Filed February 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.14 · Expires 2033-02-13 | Direct | 934,645 |
Reported balance
After 2023-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-13 · Grant · Acquired 934,645 · Balance 934,645 F1: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 13 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 13 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2023 Filed Feb 15, 2023 17:53 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 934,645 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001209191-23-009634 · doc4.xml · derivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 934,645 Underlying: Common Stock · 934,645 shares Expires 2033-02-13 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 13 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 13:43 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 5,000 | $0.25 | $1,272.50 |
DisclosureSEC source: 0001209191-22-045524 · doc4.xml · nonDerivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 16:23 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 10,000 | $0.37 | $3,700.00 |
DisclosureSEC source: 0001209191-22-018101 · doc4.xml · nonDerivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:55 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 402,900 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001209191-22-006519 · doc4.xml · derivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,900 Underlying: Common Stock · 402,900 shares Expires 2032-02-01 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:31 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 307,300 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007736 · doc4.xml · derivative · entry 2 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,300 Underlying: Common Stock · 307,300 shares Expires 2031-02-02 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022 Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:31 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 307,300 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007736 · doc4.xml · derivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,300 Underlying: Common Stock · 307,300 shares Expires 2031-02-02 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 17:18 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 2,000 | $4.25 | $8,500.00 |
DisclosureSEC source: 0001209191-20-019954 · doc4.xml · nonDerivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 21:28 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 226,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001209191-20-017408 · doc4.xml · derivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,000 Underlying: Common Stock · 226,000 shares Expires 2030-03-06 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 6, 2021, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 6, 2021. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 16:07 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,000 | $4.38 | $4,380.00 |
DisclosureSEC source: 0001209191-19-055930 · doc4.xml · nonDerivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 13:50 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,500 | $5.48 | $8,212.95 |
DisclosureSEC source: 0001209191-19-046252 · doc4.xml · nonDerivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 13:48 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,500 | $6.00 | $9,000.00 |
DisclosureSEC source: 0001209191-19-045684 · doc4.xml · nonDerivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Read SEC document |
| May 14, 2019 Filed May 15, 2019 13:56 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,000 | $7.23 | $7,226.60 |
DisclosureSEC source: 0001209191-19-029852 · doc4.xml · nonDerivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 14:32 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 5,000 | $6.85 | $34,258.50 |
DisclosureSEC source: 0001209191-19-019602 · doc4.xml · nonDerivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:44 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 180,000 | $0.00 Strike: $6.94 | $0.00 |
DisclosureSEC source: 0001209191-19-015958 · doc4.xml · derivative · entry 1 Millian Craig Stuart · CIK 0001769163 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2029-02-28 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 28, 2020, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 28, 2020. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 28, 2020, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 28, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.